Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C-type lectin domain family 1, member B pseudogene (ENSG00000256626, also known as LOC100421202) is a classified pseudogene within the C-type lectin domain family. Unlike its functional paralog CLEC1B—which encodes a transmembrane receptor involved in platelet activation, immune response, and pathogen recognition—this pseudogene does not code for a protein and has no established biological or therapeutic activity. Pseudogenes arise by duplication or retrotransposition of functional genes but typically lack protein-coding capacity due to sequence disruptions. As such, this locus should not be considered a molecular target for drug development or disease intervention[3][1]. If a molecular target is required, information should be sought for the closely related C-type lectin domain family 1 member B (CLEC1B, gene symbol: CLEC1B), which is a bona fide receptor with immunological functions, not for the pseudogene.
None (not a protein, so it cannot be pharmacologically modulated)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C-type lectin domain family 1, member B pseudogene (CLEC1B pseudogene (no officially recognized abbreviation)).